Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow disability progression.

Enrollment is now ongoing in a first-in-human clinical trial testing EPI-321, an epigenetic therapy designed to address FSHD.

GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data ...

Medications that promote repair of the myelin sheath that protects nerve cells may help limit damage due to MS, a trial ...

In an exclusive Q&A, a Biogen exec discussed the developer's quest to 'rapidly' bring its experimental SMA therapy salanersen ...

With the launch of a U.S. trial, a treatment using the B-cell medicine BE-101 has been given to a hemophilia B patient for ...

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of ...